Posttreatment with low molecular weight heparin reduces brain edema and infarct volume in rats subjected to thrombotic middle cerebral artery occlusion.
Low molecular weight heparin (LMWH) has similar efficacy to unfractionated heparin with less hemorrhagic complications. We studied the neuroprotective effect of LMWH on a rat model of focal-ischemia. Our results revealed that treatment with LMWH at 1 and 3 h following thrombotic MCA occlusion reduced brain edema and infarct size and improved clinical outcome. Treatment with LMWH initiated at 6 h after thrombin injection only partially ameliorated brain damage.
Li
P A
PA
Department of Medicine (Neurology), The University of Alberta Hospital, Stroke Research Centre and The Saskatchewan Stroke Research Centre, Saskatoon, Canada.
He
Q P
QP
Siddiqui
M M
MM
Shuaib
A
A
D000818:Animals; D001929:Brain Edema / Q000188:drug therapy*; D002545:Brain Ischemia / Q000188:drug therapy; D002539:Cerebral Arterial Diseases / Q000503:physiopathology*; D002544:Cerebral Infarction / Q000188:drug therapy*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000494:pharmacology*; D007279:Injections, Subcutaneous; D002542:Intracranial Embolism and Thrombosis / Q000188:drug therapy*; D008297:Male; D051381:Rats; D017208:Rats, Wistar
D006495:Heparin, Low-Molecular-Weight